Zidar B L, Benjamin R S, Frank J, Lane M, Baker L H
Am J Clin Oncol. 1983 Feb;6(1):71-4.
Twenty-three patients with disseminated bony sarcoma and 23 patients with malignant mesothelioma were evaluable in a Southwest Oncology Group (SWOG) clinical trial utilizing rubidazone and DTIC. One partial remission (PR) was observed in a previously untreated patient with metastatic Ewing's sarcoma. One patient with giant cell tumor of bone had an improvement, short of PR. Thirteen patients with osteogenic sarcoma and 23 with malignant mesothelioma had no response to this combination of drugs. The major toxic effects of therapy included nausea, vomiting, and myelosuppression, especially leukopenia; no cardiac toxicity was noted. We conclude that the combination of rubidazone and DTIC is inactive in bony sarcoma and mesothelioma.
在西南肿瘤协作组（SWOG）开展的一项使用鲁比达唑和达卡巴嗪的临床试验中，23例播散性骨肉瘤患者和23例恶性间皮瘤患者可进行评估。在一名先前未接受治疗的转移性尤因肉瘤患者中观察到1例部分缓解（PR）。1例骨巨细胞瘤患者病情有所改善，但未达部分缓解。13例骨肉瘤患者和23例恶性间皮瘤患者对这种联合用药无反应。治疗的主要毒性作用包括恶心、呕吐和骨髓抑制，尤其是白细胞减少；未观察到心脏毒性。我们得出结论，鲁比达唑和达卡巴嗪联合用药对骨肉瘤和间皮瘤无效。
